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ABSTRACT
Somatic loss-of-function mutations of the additional sex combs-like
transcriptional regulator 1 (ASXL1) gene are common genetic
abnormalities in human myeloid malignancies and induce clonal
expansion of mutated hematopoietic stem cells (HSCs). To
understand how ASXL1 disruption leads to myeloid cell
transformation, we generated asxl1 haploinsufficient and null
zebrafish lines using genome-editing technology. Here, we show
that homozygous loss of asxl1 leads to apoptosis of newly formed
HSCs. Apoptosis occurred via the mitochondrial apoptotic pathway
mediated by upregulation of bim and bid. Half of the asxl1+/− zebrafish
had myeloproliferative neoplasms (MPNs) by 5 months of age.
Heterozygous loss of asxl1 combined with heterozygous loss of
tet2 led to amore penetrant MPNphenotype, while heterozygous loss
of asxl1 combined with complete loss of tet2 led to acute myeloid
leukemia (AML). These findings support the use of asxl1+/− zebrafish
as a strategy to identify small-molecule drugs to suppress the growth
of asxl1mutant but not wild-type HSCs in individuals with somatically
acquired inactivating mutations of ASXL1.
KEY WORDS: Apoptosis, Hematopoietic stem cells,
Myeloproliferative neoplasms, Tet2, Genome editing
INTRODUCTION
ASXL1 is one of three mammalian homologs of the Drosophila Asx
gene, which is highly conserved across multiple species (Fisher
et al., 2006). Its product is an epigenetic scaffolding protein that
binds to chromatin and recruits polycomb repressive complex 2
(PRC2; consisting of EZH2, EED and SUZ12), which regulates the
expression pattern of developmental genes in both hematopoietic
and nonhematopoietic systems (Scheuermann et al., 2010). The
PRC2 complex catalyzes locus-specific trimethylation of lysine 27
on histone H3 (H3K27me3), a hallmark repressive modification that
recruits the PRC1 complex (Abdel-Wahab et al., 2012a), placing
further repressive modifications on chromatin by catalyzing the
monoubiquitination of lysine 119 on histone H2A (H2AK119). The
transcriptional repression of polycomb group (PcG) target genes by
PRC1 and PRC2 is important for the maintenance of lineage-
specific gene expression programs (Müller and Verrijzer, 2009;
Pietersen and van Lohuizen, 2008; Schuettengruber et al., 2007;
Schwartz and Pirrotta, 2007). ASXL1 also associates with the
deubiquitinating enzyme BRCA1-associated protein 1 (BAP1),
which removes the ubiquitin moiety from H2AK119, thereby
promoting the expression of key target genes (Abdel-Wahab et al.,
2012a; Scheuermann et al., 2010).
ASXL1 is mutationally altered in several malignant myeloid
diseases, including myeloproliferative neoplasms (MPNs;
∼10-15%), myelodysplastic syndromes (MDS; ∼15-25%), chronic
myelomonocytic leukemia (CMML; ∼45%), and de novo (6.5%) or
secondary (30%) cases of acute myeloid leukemia (AML) (Abdel-
Wahab et al., 2011; Bejar et al., 2011; Boultwood et al., 2010a,b;
Gelsi-Boyer et al., 2012, 2010; Inoue et al., 2013). These genetic
alterations comprise either focal deletions, nonsense mutations or
insertions/deletions (indels) that lead to frameshifts. Mutations in this
gene are consistently associated with adverse outcomes, and thus
serve as independent prognostic markers (Bejar et al., 2011; Gelsi-
Boyer et al., 2012, 2010). In preclinical murinemodels, the combined
loss ofAsxl1 and Tet2 from specific hematopoietic cells resulted in an
accelerated onset of MDS (Abdel-Wahab et al., 2013).
Recent reports have called attention to the fact that nonsense and
frameshift mutations of ASXL1 in human myeloid malignancies
often truncate the protein after 404 to 800 amino acids, retaining the
ASX homology domain and truncating off the remainder of this
1541 amino acid protein, including the plant homeodomain (PHD)
domain (Asada et al., 2018; Balasubramani et al., 2015; Hsu et al.,
2017; Inoue et al., 2016; Kitamura, 2018; Metscher and Ahlberg,
1999; Nagase et al., 2018; Yang et al., 2018). A transgenic mouse
model that expresses a truncated Asxl1 protein exhibited a gain-of-
function alteration and induced myeloid malignancies (Yang et al.,
2018). However, a knock-in mouse expressing a truncated ASXL1
mutant did not exhibit myeloid cell deficiency or malignancy
(Hsu et al., 2017), raising the question of overexpression artifacts in
the transgenic mouse model. Complicating the interpretation has
been a problem in raising antibodies that recognize amino-terminal
epitopes of ASXL1, so that western blotting has been very difficult
and detailed biochemistry impossible, even in cell lines with classic
exon 11 or 12 mutations. Heterozygous ASXL1mutations that occur
in earlier exons have been documented in primary chronic
myelomonocytic leukemia samples (Abdel-Wahab et al., 2011),
suggesting that this subset have true loss of one allele, and thus that
haploinsufficiency also can contribute to the onset of hematologicReceived 25 May 2018; Accepted 29 March 2019
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malignancy. Thus, further work needs to be done to separate the
roles of haploinsufficiency from possible dominant-negative or
gain-of-function activities that may result from different classes of
ASXL1 mutations.
In humans, de novo constitutive heterozygous nonsense
mutations in ASXL1 have been identified in patients with
Bohring-Opitz syndrome, a pediatric disease associated with
developmental defects. In murine models, the hematopoietic
phenotypes of animals with loss of Asxl1 are variable. Fisher
et al. reported that haploinsufficiency of Asxl1 caused mildly
perturbed myelopoiesis, while complete knockout induced severe
hematopoietic defects and perinatal lethality but did not trigger
the development of hematologic malignancies (Fisher et al., 2010).
In another study, animals with hematopoietic-cell-specific
homozygous loss of Asxl1 developed progressive myelodysplasia
culminating in MDS, an outcome that was attributed to loss of
PRC2-mediated trimethylation of H3K27 (Abdel-Wahab et al.,
2012a, 2013). Moreover, Asxl1 loss cooperated with activated
NRAS in this model to stimulate the rapid development of AML
(Abdel-Wahab et al., 2012a). Finally, Wang et al. reported that
surviving mice with ubiquitous loss of Asxl1 had features of MDS,
while Asxl1 heterozygotes developed a milder form of the disease
(Wang et al., 2014).
Here, we established zebrafish lines with germline inactivating
mutations of asxl1 early in the coding sequence of the gene and
analyzed the effect of asxl1 deficiency on hematopoietic cells in
both embryonic and adult zebrafish. We show that asxl1 is
important for the survival of newly formed hematopoietic stem
and progenitor cells (HSPCs) as they migrate into the caudal
hematopoietic tissue of the zebrafish embryo, and that homozygous
loss of asxl1 induces mitochondrial apoptosis of HSPCs through
the activation of bim and bid. In fish with heterozygous asxl1
inactivation, half of the 5-month-old adults exhibited MPN. Among
fish that were compound heterozygous for asxl1 and tet2,
80% developed MPN, indicating that haploinsufficiency for tet2
potentiates the transforming activity of asxl1 during the
pathogenesis of MPN.
RESULTS
Generation of asxl1mutant zebrafish lines by
genome editing
The zebrafish genome contains a single zebrafish ortholog of human
ASXL1. Alignment of the predicted zebrafish and human ASXL
protein sequences showed a high level of conservation within the
important functional domains (ASXN, ASXH, ASXM1, ASXM2
and PHD) that are crucial for the ability of the protein to promote
PRC2-mediated repressive chromatin alterations through H3K27
trimethylation (Abdel-Wahab et al., 2012a; Fisher et al., 2006;
Scheuermann et al., 2010) (Fig. S1). To generate loss-of-function
alleles of the zebrafish asxl1 gene, we designed transcription
activator-like effector nucleases (TALENs) to induce premature
stop codons within the sequences encoding the catalytic ASXN
domain (Fig. 1A). One-cell-stage embryos were microinjected
with the TALEN mRNAs, grown to maturity and subsequently
outcrossed. F1 progeny were then analyzed to identify fish
harboring inherited indels that disrupted the asxl1 reading frame.
We then generated two independent mutant alleles of asxl1
(asxl1Δ10 and asxl1Δ11) that possess 10- and 11-base-pair
deletions, respectively, within exon 2 (Fig. 1B). Both TALEN-
induced deletions led to premature stop codons (Fig. 1C) that
disrupted the ASXN domain and abolished the ASXH, ASXM1,
ASXM2 and PHD domains (Fig. 1D). Thus, the asxl1Δ10 and
asxl1Δ11 lines are functionally null for asxl1. When all planned
experiments were repeated with each mutant line, similar results
were obtained. For simplicity, we present only data derived from the
asxl1Δ10 line, hereafter referred to as asxl1−/−.
Asxl1 supports the development and viability of zebrafish
To determine whether asxl1 is important for the growth and viability
of developing zebrafish, we examined the morphology of clutches of
fish derived from crosses of two heterozygous zebrafish. We found
that asxl1+/− fish develop normally and are indistinguishable from
aslxl1+/+ fish during development, although they died prematurely
starting at about 18 weeks of age (Fig. 1F). By contrast, asxl1−/− fish
were viable but appeared abnormal by 7 days post-fertilization (dpf),
when 100% of mutants (27 of 27) were shorter in length and had a
reduced dorsal-ventral size overall. These homozygous mutant fish
did not grow by 9 dpf (Fig. 1E), and the vast majority (25 out of 27)
had died by 14 dpf (Fig. 1F). To explore the death mechanism of
asxl1−/− embryos, we studied the organ development at 6 dpf and 14
dpf by histopathologic analysis. At 6 dpf, the asxl1−/− embryos
exhibited normal morphology for the muscle and intestine as
compared with asxl1+/+ embryos (Fig. 2A,D and B,E). However, by
6 dpf the liver parenchyma appeared abnormal in asxl1−/− embryos,
with atypical hepatocytes containing poorly demarcated cells with
vacuolated cytoplasm (Fig. 2C,F). By 14 dpf, the asxl1−/− zebrafish
embryos showed muscular atrophy with disorganization of muscle
fibers and loss of differentiation as evidenced by round and not
elongated nuclei compared with the normal striated muscle fibers and
elongated nuclei in the muscle of asxl1+/+ fish (Fig. 2G,J). The
intestine was also abnormal in asxl1−/− embryos, which showed
intestinal architectural atypia with significant villus blunting and
disorganized localization of cell nuclei, when compared to the normal
cell nuclei and microvilli in the asxl1+/+ intestinal epithelium
(Fig. 2H,K). Additionally, the 14 dpf asxl1−/− embryos examined
demonstrated progressive architectural distortion of the liver
parenchyma as evident by widespread atypical hepatocytes with
cell crowding and poor cell border demarcation when compared to
the asxl1+/+ embryos (Fig. 2I,L).
It seems plausible that the relative hypoplasia of the intestinal
epithelium might account in part for the runted overall appearance
of the juvenile asxl1−/− fish, because the intestinal villus normally
increases the mucosal surface 10-fold and the microvilli that make
up the normal brush border increase the absorptive surface by
20-fold. Of course, we cannot establish the precise cause of the
failure to thrive and premature death of the majority of asxl1−/−
embryos based on histology alone. However, we suspect that it can
be reversible, because the small percentage of asxl1−/− fish that
survive are initially as small as the other asxl1−/− fish, but, if they
survive, they gradually attain normal size by 5 months of age and
both males and females are fertile. Histopathological analysis of
17-month-old asxl1−/− mutants revealed that the intestine and liver
were normal (Fig. S2D-I), indicating that these fish had recovered
from early developmental hypoplasia in these organs (Fig. 2).
However, they did have decreased numbers of erythroid islands in
the kidney marrow (Fig. S2A-C), indicating that the hematopoietic
system was abnormal. Thus, asxl1 is almost always essential for
development and viability, although rare individuals can recover
normal size and survive well into adulthood.
Asxl1 is required for definitive hematopoietic stem and
progenitor cell survival
We next asked whether asxl1 is required for normal embryonic and
definitive hematopoiesis. In zebrafish with heterozygous or
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Fig. 1. Genome editing with use of transcription activator-like effector nucleases (TALENs) to generate null alleles of the zebrafish asxl1 gene. (A) Site-
specific targeting for TALEN-directed Fok1 cleavage within exon 2. (B) Nucleotide sequence alignment of the asxl1Δ10 and asxl1Δ11 zebrafish lines
compared to wild-type asxl1. Left, TALEN binding site appears in red; right, TALEN binding site appears in green. Dashes in the DNA sequence represent the
nucleotides that are deleted during repair of Fok1-induced DNA double-stranded breaks. (C) Targeted Fok1-induced mutagenic lesions in asxl1 produce
frameshift mutations that lead to truncated protein products following short regions of novel amino acids, which are indicated in purple. Red ‘X’ denotes stop
codons. (D) The truncated Asxl1 protein products predicted to be expressed in the asxl1Δ10 and asxl1Δ11 mutant lines lack all highly conserved functional
domains. Red asterisks denote stop codons. (E) asxl1−/− zebrafish larvae mutants appear shorter in length and slimmer than asxl1+/+ and asxl1+/− zebrafish
larvae at day 7 and day 9 post-fertilization. Scale bars: 200 µm. (F) Kaplan–Meier survival curves for asxl1+/+, asxl1+/− and asxl1−/− mutants during the first
35 weeks of life. Asterisk (*) at the base of first curve indicates that ∼8% of asxl1−/− fish grow to normal size and survive.
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homozygous inactivation of asxl1, there was normal development
of the embryonic erythroid, macrophage and granulocytic lineages
(Fig. S3). The number of definitive HSPCs in asxl1mutant embryos
was determined by whole-mount in situ hybridization (WISH) with
a cmyb riboprobe at both 36 hpf (Fig. 3A) and 3 dpf (Fig. 3B-E) on
the progeny of a cross between heterozygous asxl1 mutant fish. At
36 hpf, the number of newly formed HSPCs budding from the
ventral wall of the dorsal aorta appeared normal regardless of
genotype (Fig. 3A); however, at 3 dpf there was an apparent
decrease in the number of cells expressing cmyb in the caudal
hematopoietic tissue (CHT) of the asxl1−/− embryos (Fig. 3E),
compared to both asxl1 wild-type and heterozygous embryos
(Fig. 3C,D). To further confirm the cmyb WISH results shown in
Fig. 3, we crossed asxl1+/− fish with Tg(cmyb:EGFP), in which
HSPCs could be visualized by EGFP. Incrosses of these fish showed
a statistically significant (P=0.0002) reduction of EGFP+ cells at
3 dpf based on EGFP fluorescence (Fig. S4), similar to the results
we observed by WISH at 3 dpf (Fig. 3). Because cmyb+ HSPCs
were dramatically decreased in asxl1−/− embryos between 36 hpf
and 3 dpf (Fig. 3E), we postulated that the asxl1−/− HSPCs may be
undergoing apoptosis during this interval.
To address this hypothesis, we performed terminal transferase
UTP nick end labeling (TUNEL) analysis coupled with
immunohistochemistry (IHC) for cmyb/GFP in 48-hpf asxl1+/+,
asxl1+/− or asxl1−/− embryos generated in the background of the
Tg(cmyb:GFP) reporter line (North et al., 2007). Compared with
asxl1+/+ and asxl1+/− embryos, those with an asxl1−/− genotype
showed a significant increase in the number of cmyb/GFP+/
TUNEL+ cells (Fig. 3F-I). These results indicate that, although
asxl1 is not required for HSPC specification and budding from the
ventral wall of the dorsal aorta at 36 hpf, it is important for the
survival of newly formed HSPCs as they migrate into the CHT of
the zebrafish embryo.
To determine whether the progeny of surviving asxl1−/− adult
fish had defects in hematopoiesis, we compared the progeny of
incrosses of asxl1+/− fish with those of incrosses of asxl1−/− fish.
Then, we performed WISH with a cmyb riboprobe at 3 dpf to assess
the number of definitive HSPCs in embryos at that developmental
stage. There was a similar decrease in the number of HSPCs
expressing cmyb in the CHT of 3 dpf asxl1−/− embryos, whether
they arose from heterozygous (10 of 42; Fig. 4C) or homozygous
(10 of 10; Fig. 4D) incrosses, as compared to wild-type (Fig. 4A)
and heterozygous asxl1 (Fig. 4B) embryos.
We also tested whether a complete loss of asxl1 leads to defects
in hematopoiesis in adult zebrafish, as indicated by the reduction
of erythroid islands in the kidney marrow, as shown for a
representative asxl1−/− fish at 17 months of age (Fig. S2A-C).
Giemsa staining of the hematopoietic cells from kidney marrow
touch preps of seven asxl1−/− zebrafish sacrificed at 16- to
17-months of age showed a complete lack of myeloid maturation
with increased numbers of myeloblasts (Fig. 4E, blue arrows) when
compared to wild-type fish. In the absence of secondary causes,
such as toxic exposure or drug administration, arrested myeloid
maturation strongly suggests a myeloid neoplasm, and the presence
of increased myeloblasts supports a diagnosis of a disease
resembling AML. In peripheral blood smears from asxl1−/− fish,
only rare myeloblasts were present (Fig. 4E, blue arrows), which is
not an unusual feature of AML. By close examination of blood
smears from two asxl1−/− fish, we identified circulating immature
myeloid blast cells in the peripheral blood of the mutant zebrafish
(3 of 250 blood cells in fish 1, and 4 of 250 blood cells in fish 2) that
were not evident in wild-type fish (0 in 250 blood cells in fish 1, and
0 in 250 blood cells in fish 2; Fig. 4E, blue arrows). Thus, complete
loss of asxl1 leads, after 16-17 months, to a disease resembling
AML in zebrafish, likely after accumulation of additional mutations
or epigenetic alterations.
Fig. 2. Asxl1 loss affects organ development.
Histopathological analysis of the muscle, intestine and
liver development with hematoxylin and eosin staining in
5 asxl1+/+ and 5 asxl1−/− mutants at 6 dpf and 14 dpf.
Muscle (A,D) and intestine (B,E) development had no
difference between asxl1+/+ and asxl1−/− embryos at
6 dpf. Liver parenchyma at 6 dpf appeared abnormal with
vacuolated cells in asxl1−/− embryos (F) compared with
asxl1+/+ embryos (C). At 14 dpf, muscular atrophy was
shown in asxl1−/− embryos (J) compared with normal
striated muscle in asxl1+/+ embryos (G). Intestine in
asxl1−/− embryos was abnormal with villus blunting (K)
compared with normal nuclei and microvilli in the
asxl1+/+ embryos (H). The asxl1−/− embryos exhibited
progressive liver architectural distortion (L) compared to
asxl1+/+ embryos (I).
4



















loss of HSPCs in asxl1mutants
To investigate the mechanism by which HSPCs undergo apoptosis
in 48 hpf asxl1−/− embryos, we performed quantitative real-time
PCR (qPCR) on mRNA isolated from the CHT region of 48 hpf
asxl1+/+, asxl1+/− and asxl1−/− zebrafish embryos (Fig. 5A,B). We
analyzed expression of p53 (tp53) as well as both pro-apoptotic
( puma, bim, bid, bik and bax) and anti-apoptotic (bcl2, bcl-xL and
mcl1a) members of the Bcl2 family. There was significant
overexpression of bim and bid in asxl1−/− compared to asxl1+/+
and asxl1+/− embryos (Fig. 5A; P<0.05) but no change in p53,
puma, bik or bax expression. Additionally, we observed a
significant decrease in bcl2 expression but no change in the levels
of bcl-xL or mcl1a in asxl1−/− embryos (Fig. 5B). These data
suggest that changes in bim, bid and bcl2 mediate HSPC apoptosis
in 48 hpf asxl1−/− embryos, thereby leading to loss of cmyb+ cells in
the CHT at 3 dpf.
To test whether bim is required for the loss of asxl1−/−HSPCs, we
used a bim-mutant zebrafish line (bcl2l11zdf19) that was generated
by retroviral insertional mutagenesis (Golling et al., 2002). This line
(hereafter referred to as the bim mutant line) harbors a retroviral
insertion located within the coding sequence of bim exon 2 and lies
upstream of the BH3 domain required to induce apoptosis, thereby
creating a loss-of-function allele of bim. We crossed the bimmutant
line into our asxl1+/− zebrafish line and analyzed the progeny for
cmyb expression by WISH at 3 dpf (Fig. 5C,D). Our data show that
bim is required for the loss of cmyb+ HSPCs in the CHT of asxl1−/−
zebrafish at 3 dpf. We next asked whether bid is required for
apoptosis in 48 hpf asxl1−/− zebrafish HSPCs. Thus, after
incrossing asxl1+/− adult zebrafish and injecting the progeny with
a bid-specific splice-blocking morpholino (MO) (Kratz et al., 2006;
Pyati et al., 2011), we performed WISH for cmyb at 3 dpf,
subsequently genotyped the embryos for the asxl1 mutation and
quantified the results of the cmyb WISH (Fig. 5E,F). Remarkably,
knockdown of bid also partially rescued the loss of cmyb+HSPCs in
the CHT of asxl1−/− zebrafish at 3 dpf.
To determine whether the decrease in bcl2 expression could
contribute to the apoptosis observed in 48 hpf asxl1−/− HSPCs, we
incrossed asxl1+/− adult zebrafish and injected the progeny with
mRNA encoding bcl2 or a control gene. We again performedWISH
for cmyb at 3 dpf, genotyped the embryos and quantified the results
(Fig. 5G,H). We found that overexpression of bcl2 rescued most of
Fig. 3. Loss of asxl1 induces apoptosis in cmyb-expressing embryonic HSPCs. WISH for cmyb was performed at 36 hpf (A) and 3 dpf (B-E) in asxl1+/+,
asxl1+/− and asxl1−/− zebrafish embryos. Boxes in panel B are shown at higher magnification in C-E. (F-H) HSPCs (GFP; green) and cells undergoing
apoptosis (TUNEL, TMR red, Roche) in the CHTof 48-hpf asxl1+/+, asxl1+/− and asxl1−/− zebrafish embryos in the Tg(cmyb:EGFP) reporter line background were
identified by immunofluorescence microscopy following a dual TUNEL/anti-GFP assay. Arrows indicate apoptotic HSPCs with combined EGFP and
DMR red fluorescence signals. (I) cmyb:GFP+/TUNEL+ cells in asxl1+/+, asxl1+/− and asxl1−/− were quantified as a percentage of total cmyb:GFP+ cells.
Bars represent the mean and s.e.m. for 8-9 embryos each. Unpaired Student’s t-tests and Prism software were used to determine the P-value for each
genotypic group compared with control cells.
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the apoptotic asxl1−/− HSPCs. To show these findings by confocal
fluorescence microscopy, we repeated the rescue assay in asxl1−/−,
asxl1+/− and asxl1+/+ embryos bred into the Tg(cmyb:EGFP)
background, in which HSPCs could be visualized by expression of
EGFP. Statistically significant partial rescue of EGFP+ HSPCs was
observed at 3 dpf in asxl1−/− embryos injected with each of the bim
MO and bid MO, and also with bcl2 mRNA (Fig. S5). This
experiment indicated that the apoptosis that occurred shortly after
budding of asxl1−/− HSPCs from the hemogenic endothelium was
due to the combined action of the BH3-only proteins Bim and Bid,
and that it could be blocked by overexpression of bcl2. Thus, death
of asxl1−/− HSPCs occurred through programmed cell death
mediated by the intrinsic mitochondrial apoptotic pathway.
Combined loss of asxl1 and tet2 potentiates the
development of MPN and leads to AML in a subset of adult
zebrafish
We recently described a zebrafish model of MDS in which both
tet2−/− and tet2+/− fish develop trilineage dysplasia at 11 months of
age and full-blown MDS with anemia by 24 months (Gjini et al.,
2015). In human myeloid malignancies, inactivating mutations of
ASXL1 and TET2 often occur together in the same patient’s
malignant cells (Abdel-Wahab et al., 2012b; Patnaik et al., 2016),
suggesting that loss of these two tumor suppressors may act
synergistically in myeloid transformation. To pursue this
hypothesis, we intercrossed the tet2+/− and asxl1+/− lines and
then inbred the compound heterozygous progeny to generate each of
the genotypes that was relevant to our experiment (asxl1+/+tet2+/+,
asxl1+/−tet2+/+, asxl1+/−tet2+/− and asxl1+/−tet2−/−). These
progenies were identified through genotyping at 2 months of age
and were closely monitored for survival. At 5 months of age, May–
Grünwald–Giemsa (MGG) staining of kidney marrow and
peripheral blood smears representing 9-11 individual fish per
genotype (Fig. 6A-H) revealed an increase in the number of
myelomonocytes (Fig. 6A-D, light-blue arrows) in the kidney
marrow of a subset of animals with heterozygosity for asxl1
[asxl1+/−tet2+/+ (5 of 11); asxl1+/−tet2+/− (8 of 11) and
asxl1+/−tet2−/− (3 of 10)], which is diagnostic of MPN.
Moreover, 2 of 10 asxl1+/−tet2−/− fish had high numbers of
immature myeloid cells lacking differentiation, which is indicative
of AML (Fig. 6D, black arrows). Analysis of peripheral blood
smears showed an aberrant increase in circulating immature red
blood cells (Fig. 6E-H, orange arrows) in a subset of animals
heterozygous for asxl1 [asxl1+/−tet2+/+ (5 of 11), asxl1+/−tet2+/−
(8 of 11) and asxl1+/−tet2−/− (3 of 10)]. These results demonstrate
the rapid onset of MPN in fish with heterozygous loss of asxl1 and
Fig. 4. Complete loss of asxl1 leads to AML in
zebrafish. WISH for cmyb was performed at 3 dpf in
asxl1+/+ (A), asxl1+/− (B) and asxl1−/− (C) zebrafish
embryos obtained from a cross of two asxl1+/− fish.
(D) WISH for cmyb was performed at 3 dpf in asxl1−/−
zebrafish embryos obtained from a cross of two asxl1−/−
fish. Insets show a higher magnification of the CHT in
each panel. (E) MGG staining was performed on kidney
marrow smears and peripheral blood smears of asxl1+/+
and asxl1−/− fish at 17 months of age. Normal
maturation and morphology are shown across a
spread of blood cells in the kidney marrow of the
asxl1+/+ zebrafish. In the asxl1−/− fish, the kidney
marrow is replaced with immature myeloid blast cells
in a pattern resembling AML. Circulating immature
myeloid blast cells were observed in the peripheral
blood of the asxl1−/− zebrafish, but not asxl1+/+ fish.
Erythrocytes, black arrow; myeloid cells, green arrow;
blast cells, blue arrow; lymphocytes, red arrow.
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Fig. 5. See next page for legend.
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tet2, with AML apparently being restricted to asxl1+/− fish with loss
of both tet2 alleles.
To assess the consequences of asxl1 heterozygosity on
hematopoiesis more rigorously, we quantified 4 major categories of
blood cell populations (erythrocytes, lymphocytes, myelomonocytes
and progenitor cells) with respect to their relative numbers in the
kidney marrow and their absolute numbers per liter of peripheral
blood. Forward- and side-scatter flow cytometry was performed
individually for wild type or asxl1 heterozygous mutants, alone or in
combination with hetero- or homozygosity for tet2 (i.e. 6 genotypes,
9-11 fish per group). Analysis of the relative numbers of each cell
type in the kidney marrow (Fig. 6I-L and Fig. S6) revealed a
significant decrease in the erythroid cell fraction in asxl1+/−tet2+/+
and asxl1+/−tet2+/− fish, but not in asxl1+/−tet2−/− fish, compared
to wild type (Fig. 6I). The lymphocyte fraction, by contrast,
did not differ appreciably, consistent with findings in Fig. 6A-D.
Myelomonocytes increased significantly in asxl1+/−tet2+/+,
asxl1+/−tet2+/− and asxl1+/−tet2−/− fish compared to wild type
(Fig. 6K). Finally, there was a significant decrease in the progenitor
cell fraction of asxl1+/−tet2+/− fish but not in those with other
genotypes, compared to wild type (Fig. 6L). Analysis of absolute cell
counts in peripheral blood for each blood cell type (Fig. 6M-P)
supported the results based on cell fraction, with contribution of
homozygous loss of tet2 becoming more evident. Thus, regardless
of tet2 status, heterozygosity for asxl1 consistently increased
myelomonocytes in the kidney marrow and lowered absolute
numbers of circulating erythrocytes, both characteristic features of
human MPN. Notably, however, homozygous loss of tet2 leads to
AML in 20% of asxl1 heterozygotes, suggesting a synergistic
interaction between these two genes when they are both mutated in
the same myeloid progenitors.
DISCUSSION
The ASXL1 gene is often somatically mutated in patients with
hematopoietic malignancies such as MDS, MPN and AML,
generally through acquired heterozygous nonsense or frame-shift
mutations (Abdel-Wahab et al., 2011; Bejar et al., 2011; Boultwood
et al., 2010a,b; Gelsi-Boyer et al., 2012, 2010; Inoue et al., 2013).
Here, we report a zebrafish model with germline asxl1 inactivation
and the unique property that half of the fish with heterozygous
mutations develop MPNs by 5 months of age, characterized by
increased numbers of myelomonocytes in the kidney marrow
and peripheral blood together with anemia. In this context, our
preclinical model shows the considerable consequences in vivo of
haploinsufficiency for a true null allele of asxl1 in terms of myeloid
malignancy, because themutationswe havemade truncate the protein
after amino acids 39 or 62, which is upstream of or internal to each of
the conserved domains of ASXL1 (see Fig. 1D). Based on recent
publications suggesting that an amino-terminal portion of ASXL1
with dominant-negative or neomorphic activity could be expressed in
some patients with hematologic malignancy (Asada et al., 2018;
Balasubramani et al., 2015; Hsu et al., 2017; Inoue et al., 2016;
Kitamura, 2018; Nagase et al., 2018; Yang et al., 2018), it will also be
important in the future to produce zebrafish models that introduce
asxl1 frame-shift mutations and premature termination in exon 11 or
early in exon 12 to assess additional phenotypes that may accompany
a truncated protein arising from this gene.
Abdel-Wahab and colleagues (2013) used an elegant conditional
Asxl1 knockout approach inserting two loxP sites that flanked exons
5-10 to generate their murine model. Hematopoietic-cell-specific
homozygous deletion of Asxl1 resulted in MDS characterized by
progressive, multilineage cytopenias and dysplasia accompanied by
increased numbers of less differentiated hematopoietic stem and
progenitor cells. TheMDS phenotype in Asxl1 haploinsufficient mice
at 6-12 months (Abdel-Wahab et al., 2013) was different from the
very penetrant and earlyMPNphenotype (5 months) that we observed
in the asxl1 mutant zebrafish model. Thus, subtle differences exist in
the myeloid phenotypes and possibly the affected downstream
pathways disrupted by asxl1 haploinsufficiency in these two
vertebrate models of myeloid malignancy. The disease was
transplantable, with a shorter latency for myeloid malignancies with
Asxl1 null hematopoietic cells versus those with haploinsufficiency.
ASXL1 loss in this model leads to a global reduction of PRC2-
mediated trimethylation of H3K27 and thus causes dysregulated
expression of key regulators of hematopoiesis, including HOXA9
(Abdel-Wahab et al., 2013). In results similar to those of Abdel-
Wahab et al. in mice (Abdel-Wahab et al., 2013), we show that tet2
and asxl1 cooperate in the pathogenesis of myeloid malignancies in
zebrafish, although the phenotypes in zebrafish that we report are
focused on MPN progressing to AML, rather than progressive MDS
as observed in the murine model.
Wang and colleagues (2014) developed a constitutive Asxl1murine
knockout line by disrupting the translation start site of Asxl1. A small
fraction of the homozygous knockout mice survived for a maximum
of 18-42 days, and some of these developed MDS with anemia,
thrombocytopenia and neutropenia. However, heterozygous Asxl1+/−
animals in this model developed only minimal abnormalities in
myeloid cell morphology without significant alterations in blood
counts, similar to the constitutive Asxl1 knockout mice reported by
Fisher et al. (2010) and Wang et al. (2014). Thus, haploinsufficiency
for ASXL1, the main acquired genetic abnormality in human myeloid
malignancies, does not by itself seem to reproducibly induce
hematopoietic malignancies in mice.
Homozygous loss of asxl1 in our zebrafish model caused profound
hypoplasia of the gastrointestinal system, with underdeveloped
epithelium, resulting in very small larvae and near-complete lethality
by 14 dpf. Interestingly, about 8% of the asxl1−/− zebrafish larvae in
our study survived, regained normal size and became fertile by
3 months of age. Thus, in the zebrafish, the total absence of asxl1
appears to delay or prevent the emergence of pathways important for
gastrointestinal development but, with time, these pathways are
restored in a small fraction of the fish, enabling their unimpeded
Fig. 5. Overexpression of bim and bid mediates apoptosis in asxl1−/−
HSPCs. (A,B) Quantitative PCR was performed with cDNA isolated from the
trunks of 48 hpf asxl1+/+, asxl1+/− and asxl1−/− zebrafish embryos to quantify
the expression of pro-apoptotic (A) and anti-apoptotic (B) members of the Bcl2
family. Expression levels are shown relative to β-actin. The values aremeans of
triplicate runs with s.e.m. Statistical significance was determined with unpaired
Student’s t-test. Results from a single experiment are shown; however, four
independent experiments were performed for both panels A and B with similar
results. (C) WISH to detect cmyb with the indicated genotypes at 3 dpf,
showing that the loss of HSPCs in asxl1−/− fish is rescued by loss of bim.
(D) Cropped CHT regions from panel C were quantified with use of 98 embryos
per genotypewith ImageJ software. (E)WISH to detect cmybwas performed at
3 dpf for embryos with the indicated genotypes that were injected with 16 ng of
either bidmorpholino or control morpholino, showing that the loss of HSPCs in
asxl1−/− fish is rescued by loss of bid. (F) Cropped CHT regions from panel E
were quantified with use of 60 embryos per genotype and ImageJ software.
(G)WISH to detect cmybwas performed at 3 dpf for embryos with the indicated
genotypes that were injected with 100 ng/µl mRNA encoding either Bcl2 or
GFP. Overexpression of bcl2 rescued the loss of HSPCs in asxl1−/− fish.
(H) CroppedCHT regions from panel G were quantified with use of 70 embryos
per genotype and ImageJ software. In panels D, F and H, black bars
representing the median values. Statistical analysis was done with Prism
software. Unpaired Student’s t-tests were performed in Prism software to
determine the P-value for each genotype group compared to controls.
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progression to normal adulthood. The hematopoietic phenotype of
adult asxl1−/− fish was profound in that all of the surviving animals
that we examined had kidney marrow morphology suggestive of
AML by 17 months of age.
We did not observe craniofacial abnormalities or
anophthalmia, both of which have been reported in the murine
models with Asxl1 deletion. For example, homozygous
inactivation of Asxl1 by Abdel-Wahab and colleagues (2013) in
nearly all tissues with EIIa-cre caused embryonic lethality
and craniofacial abnormalities, including microophthalima/
anophthalmia. Similarly, Wang and colleagues (2014) reported
that homozygous constitutive inactivation of Asxl1 in mice led to
dwarfism and anophthalmia. Fisher et al. (2010) also developed a
constitutive loss-of-function murine model, with insertion of a
pgk promoter-driven neomycin-resistance cassette into exon 5.
In retrospect, this alteration appears to be hypomorphic, as
Fig. 6. See next page for legend.
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homozygous insertion produced only modest homeotic
transformation of the axial skeleton and runting.
We observed that asxl1−/− fish have defects in the earliest phases
of definitive hematopoiesis, in that homozygous loss of asxl1 led
to reduced numbers of HSPCs by 72 hpf. We also noted that
specification of definitive HSCs from the ventral wall of the dorsal
aorta occurs normally in asxl1−/− fish, whereas the newly formed
HSCs rapidly succumb to apoptosis, such that only 40% of normal
numbers remain by 72 hpf. Importantly, the increased apoptosis that
we observed is mediated through the mitochondrial pathway, as it
can be rescued by Bcl2. We further show that the death of migratory
HSPCs is induced by upregulation of the BH3-only pro-death
proteins Bim and Bid, as knockout of either of these genes could
partially rescue the affected HSPCs in asxl1−/− animals.
Because of the optical clarity of zebrafish embryos and juvenile
fish, the asxl1 mutant zebrafish lines reported here provide definite
imaging advantages for assessing the pathways involved in the
initiation and maintenance of MPNs arising from this deletion.
These same advantages permit the analysis of chemical libraries of
US Food and Drug Administration (FDA)-approved drugs for their
ability to inhibit zebrafish HSPCs in order to discover drugs that are
synthetic lethal with asxl1 loss for the suppression of HSPC growth
and survival. A very successful screen of HSPCs in zebrafish
embryos by North and coworkers (2007) identified PGEII as a
promoter and indomethacin as a suppressor of the growth of HSPCs
in normal embryos. This same approach could be applied to identify
drugs that specifically suppress HSPCs with haploinsufficiency for
ASXL1. Such drugs might prove active in human MPN cases with
ASXL1-inactivating mutations. Moreover, clonal hematopoiesis,
arising in 10% of individuals over 65 years of age, has been linked
to clonal expansion of HSPCs with mutations of several genes,
including the epigenetic modifiers DNMT3A, TET2 and ASXL1
(Genovese et al., 2014; Jaiswal et al., 2014). Importantly, this
age-related defect predisposes to the development of hematologic
malignancy (Corces-Zimmerman et al., 2014; Hirsch et al., 2016;
Shlush et al., 2014) and more recently was related to a doubling of
the risk of coronary artery disease (Jaiswal et al., 2017). Currently,
there is a lack of safe and efficient drugs for inhibiting mutant but
not wild-type HSPCs. The zebrafish model described here could be
exploited to identify small-molecule drugs already in human use
that could be repurposed for the suppression of ASXL1 mutant
HSPCs and their progeny.
MATERIALS AND METHODS
Zebrafish maintenance
Wild-type stocks of AB fish, and transgenic and mutant lines were
maintained according to a previously reported protocol (Bolli et al., 2010).
Animal handling was approved by the Dana-Farber Institutional Animal
Care and Use Committee. The Tg(cmyb-EGFP) line is described elsewhere
(North et al., 2009), as are the details of a developmental staging system
(Metscher and Ahlberg, 1999). For all experiments, zebrafish embryos were
cultured in ‘egg water’ consisting of 0.03% sea salt and 0.002% Methylene
Blue as a fungicide. To inhibit pigment formation and facilitate in situ
hybridization, we incubated embryos with 0.0045% 1-phenyl-2-thiourea
(Sigma).
TALEN and targeting-vector construction and microinjection
The pair of TALENs recognizing exon 2 of the zebrafish asxl1 gene was
designed with ZiFiT Targeter software (http://zifit.partners.org/ZiFiT/), and
the TAL effector repeats were constructed by the ‘unit assembly’ method
described previously (Sander et al., 2011). TALEN mRNAwas synthesized
by in vitro transcription using the SP6 mMESSAGE mMACHINE Kit
(Ambion). Approximately 50 pg of mRNAs encoding each of the two
TALENs were injected into 1-cell-stage zebrafish embryos. The genomic
DNAwas isolated from a mixture of 3 embryos at 48 hpf, and the fragments
containing the TALEN target site were amplified by PCR and sequenced
with specific primers to examine the efficiency of the TALENs.
Morpholinos and mRNA microinjection
P53 morpholino, bid morpholino and control morpholinos were purchased
from Gene Tools LLC (all the sequences are listed in Table S1). Capped
mRNAs (bcl2-mCherry) were transcribed from linearized PCS2+ plasmids
(mMessage Machine; Ambion), purified, and diluted to 100 ng/ml for
injection at the 1-cell stage of development.
Whole-mount in situ hybridization
Digoxigenin-labeled RNA probes were transcribed using linearized
constructs with T3 or T7 polymerase (Ambion). Embryos at the desired
time points were fixed overnight in 4% paraformaldehyde (PFA) at 4°C.
Whole-mount in situ hybridization (WISH) was performed as described
(North et al., 2009).
Cell suspension preparation and flow cytometry
Adult fish were anesthetized with 0.02% tricaine before kidney removal.
The kidney was dissected and placed in ice-cold 0.9×PBS containing
5% fetal calf serum (FCS). Single-cell suspensions were generated by
aspiration, followed by mild teasing of the kidney on a 40-μm nylon mesh
filter with a pipette tip. Blood cell populations were analyzed on a BD FACS
Aria with high forward scatter/side scatter (FSC/SSC), as previously
described (Traver et al., 2003). Data analyses were performed with FlowJo
software (TreeStar, Ashland, OR, USA). Statistical analysis was done with
Prism software with unpaired Student’s t-tests to determine the P-value for
each genotype group compared with controls.
Peripheral blood cell counts
Adult fish were anesthetized with 0.02% tricaine, and 1 µl peripheral blood
was obtained by cardiac puncture diluted in 499 µl of 0.9×PBS containing 5%
FCS. Ten microliters of heparin sodium (1000 units/ml) was added to prevent
blood coagulation, and 20 µl of Flow-Check fluorospheres (106 fluorospheres/
ml; Beckman Coulter, Inc.) was added to this solution. The number of cells
corresponding to 1000 counted fluorospheres was obtained with use of the
BDFACSAria with high FSC/SSC, as previously described (Gjini et al.,
2015). Data analyses were performed with FlowJo software (TreeStar).
Fig. 6. Combined loss of asxl1 and tet2 leads to MPN and AML in a subset
of adult zebrafish.Morphological and quantitative analysis of blood cell types
in the kidneymarrowand peripheral blood of 5-month-old fish with the indicated
genotypes. MGG staining was performed on kidneymarrow smears. (A-H) Red
arrows denote mature erythrocytes; light blue arrows denote myelomonocytes;
green arrows denote lymphocytes; black arrows denote progenitor cells; and
orange arrows denote immature red blood cells. (A) In wild-type fish, the kidney
marrow hematopoietic cells showed normal maturation and morphology.
(B) Five of 11 asxl1+/−tet2+/+ fish had an increased number of mature myeloid
cells, indicating MPN; the remaining 6 fish had normal morphology. (C) Eight
of 11 asxl1+/−tet2+/− fish showed an increased number of maturemyeloid cells,
indicating MPN. (D) Two of 10 asxl1+/−tet2−/− fish showed increased myeloid
blast cells, indicating AML. Four of the remaining 8 fish had MPN, while the
other 4 had normal morphology. (E-H) Analysis of peripheral blood smears
by MGG staining. (E) Wild-type fish had normal maturation and morphology of
the blood cells. (F) Five of 11 asxl1+/−tet2+/+ fish showed rounded circulating
immature red blood cells and increased mature myeloid cells. (G) Eight of
11 asxl1+/−tet2+/− fish showed immature rounded circulating red blood cells.
(H) Two of 10 asxl1+/−tet2−/− fish showed an increased number of myeloid blast
cells, myelomonocytes and immature erythrocytes. (I-L) Forward- versus
side-scatter analysis of kidney marrow cell populations in 5-month-old fish
with the indicated genotypes. (M-P) Forward- versus side-scatter analysis of
absolute cell numbers per liter of blood in 5-month-old fish with the indicated
genotypes, showing increased myelomonocytes and decreased red blood
cells in asxl1+/− fish. A subpopulation of asxl1+/−tet2−/− fish showed increased
progenitor cell numbers in kidney marrow and blood. Mean values with s.e.m.
are shown. Statistical analysis was done with Prism software. Unpaired
Student’s t-tests were performed in Prism to determine the P-value for
each genotypic group compared with controls.
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RNA from the clipped caudal hematopoietic tissue region from asxl1+/+,
asxl1+/− and asxl1−/− embryos was extracted with TRIZOL reagent
(Invitrogen). cDNA was synthesized with Superscript III (Invitrogen),
while quantitative real-time PCR (qPCR) was carried out on a ViiA 7
real-time PCR system using SYBR Green. The fold change was calculated
by the ΔΔCT method normalized to β-actin (see Table S1 for the
primer sequences).
Kidney smears and MGG staining
The kidney was dissected and smeared on glass slides, which were then
fixed and stained with MGG stain (Sigma-Aldrich) according to the
manufacturer’s instructions and visualized with an Olympus BX51
microscope (Olympus).
Phosphorylated histone H3 labeling and TUNEL assay
TUNEL was performed with the In-Situ Cell Death Detection kit (POD:
Roche) according to the manufacturer’s recommendations. Phosphorylated
histone H3 labeling of fixed embryos was performed with the rabbit anti-
phosphohistone H3 antibody (Santa Cruz) at 4°C overnight and visualized
with Alexa-Fluor-488 goat anti-rabbit secondary antibody (Invitrogen).
Images of zebrafish immunofluorescence staining or live transgenic embryos
were taken with a Leica SP5X scanning confocal microscope. The embryos
were mounted in 1% low-melt agarose and the confocal images were captured
with 20× objective. Fluorescence-positive cells were counted in each individual
slice and sum numbers were analyzed with the GraphPad Prism 7 software
using the two-tailed Student’s t-test. The optical slice thickness is 3 µm.
Genotyping
For embryo stages and adult stages, asxl1 mutant fish were individually
genotyped using one forward (5′-GGTGAATGTCTTTGCCGTTC-3′)
and one reverse (5′-GAGAGTGAAGCATGGTGACAAG-3′) primer. The
zebrafish bim mutant line (insertion mutation) was crossed with the asxl1
mutant line in the rescue experiment. Genotyping primers are listed in Table S1.
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Fig. S1. Alignment of the predicted zebrafish and human proteins showed a high level of conservation for 
the ASXN, ASXH, ASXM1, ASXM2 and PHD domains.  































Fig. S2. Histopathological analysis of kidney, intestine and liver development in 17-month-old asxl1+/+ 
and asxl1+/-  and asxl1-/-  fish. Results revealed that intestine (D, E and F) and liver (G, H and I) was normal 
and similar to that of the fish, indicating that these fish recovered from early developmental hypoplasia in these 
organs. However, asxl1-/-  mutants did have decreased numbers of erythroid islands in the kidney marrow 
compared with asxl1+/+ and asxl1+/-  fish (A, B and C), indicating that the hematopoietic system is abnormal 
in these animals. Area encircled with black line indicates erythroid islands. The quantification of erythroid 
islands was shown in (J), with the black bars representing the median values. ns p>0.05, *p<0.05, **p<0.01 by 
two-tailed unpaired t-test. 































Fig. S3. Whole-mount in situ hybridization (WISH) for gata-1 (22 hours-post-fertilization), l-plastin and 
mpx (22 hours-post-fertilization) was performed in asxl1+/+, asxl1+/-, asxl1-/-, asxl1+/+tet2 -/-, asxl1+/-tet2 
-/-  and asxl1-/-tet2 -/- zebrafish embryos. This assay shows that there is no difference in the number of cells 
expressing gata-1, l-plastin and mpx among all the different genotypes.   































Fig. S4. The number of HSPCs in the CHT is reduced in the asxl1 -/- embryos at 3 dpf. (A-C) EGFP+ 
HSPCs in asxl1 +/-, asxl1 +/- and asxl1 -/- embryos.  (D) Statistical analysis of HSPC numbers in asxl1 +/-, 
asxl1 +/- and asxl1 -/- embryos indicate that EGFP+ HSPCs are decreased in CHT region in asxl1 -/- embryos 
at 3 dpf. 































Fig. S5. EGFP+ HSPCs in asxl1 +/+, asxl1 +/- and asxl1 -/- embryos at 3 dpf. Knockdown of bim (D-F) and 
bid (G-I) or overexpression of bcl2 (J-L) each were able to partially rescue HSPC numbers in asxl1 -/- embryos 
compared with control embryos.  This result is expected because mitochondrial intrinsic programmed cell death 
depends on the combined activities of BH3-only pro-apoptotic proteins and is blocked by prosurvival proteins 
like bcl2. 





























































Fig. S6. Forward versus side scatter analysis plots for kidney marrow cell populations in 5-month-old. 
asxl1 +/+ (A), tet2 +/- (B), tet2 -/- (C), asxl1 +/- (D), asxl1 +/-;tet2 +/- (E) and asxl1 +/-;tet2 -/- (F).  
Erythrocyte cell contours are circled in red, lymphocyte cell contours are circled in green, myelomonocytes cell 
contours are circled in blue, and progenitor cell contours are circled in purple. 
































p53 MO GCGCCATTGCTTTGCAAGAATTG 
Control MO GGTCAGCATTCAAGAGACCATGCAT 
bid MO GGTCAAAGTTCCTGTTGAAGTCCAT 
bim MO TACTAAACTCCCGTTTGAACTCACC 
bim genotyping-WT-f GAGCAAACGCTGGCCAATGGCCCGG 
bim genotyping-WT-r GTCCGTCTTGCGCTTCGGAAATATT 
bim genotyping-mutant-f CGACAGCGATTCTGTGCCAGGTTC 
bim genotyping-mutant-r GACGCAGGCGCATAAAATCAGTC 
p53 rt-f ttcgagccactgccatctat 
p53 rt-r ttgccctccactcttatcaaa 
puma rt-f caggacagtctactcagggaca 
puma rt-r ctagcagatctggcagaggaa 
bim rt-f agttcaatcgcctctactgtga 
bim rt-r gacgatggcgtgttcgtt 
bid rt-f gcgacctacagagaccttttaca 
bid rt-r gagcctcttctgcattgactg 
bax rt-f gtttgcagcagatcggagat 
bax rt-r ggccactctgatgaagacg 
bik rt-f ctagaaagtgggcagcttgg 
bik rt-r tgccagggtgtatgtagtgc 
bcl2 rt-f tggcgtcccaggtagataat 
bcl2 rt-r accgtacatctccacgaagg 
bcl Xl rt-f cgtcctggcactacactgaa 
bcl XI rt-r tgtcatctgctttccacactg 
mcl1 rt-f gcaggactggatcctcaaaa 
mcl1 rt-r ccatgacggacaacagactc 
b-actin rt-f TACAATGAGCTCCGTGTTGC 
b-actin rt-r ACATACATGGCAGGGGTGTT 
Table S1. All primers sequences used in this paper, including genotyping primers and real-time PCR 
primers. 
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